SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline, particularly the FDA-cleared expansion of its REGAIN glioblastoma trial and upcoming clinical updates, alongside completed enrollment in its pancreatic-cancer IMPACT study. Traders are broadly bullish on the catalyst pipeline, though some are waiting for larger-cohort data to confirm the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook after earnings, amid softer PC demand and manufacturing constraints, triggered a steep selloff and analyst downgrades. Traders are divided between calling the decline an overreaction and buying the dip, and seeing it as evidence of deeper execution and turnaround problems.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing attention around its monthly distribution and ex-dividend schedule as Nasdaq weakness weighs on the ETF. Traders are focused on the income and buying the dip, while others note that its covered-call strategy can cushionbut not preventlosses and may limit upside in a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?

Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and costs loom.

BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock

Equity

Immix Biopharma’s latest clinical results showed strong patient responses to its lead CAR-T candidate as the biotech firm prepares for a planned regulatory filing in 2027.

Immix Biopharma's NXC-201 Shows 89% Complete Response Rate In AL Amyloidosis

(RTTNews) - Tuesday, Immix Biopharma (IMMX) said an interim Phase 2 NEXICART-2 update showed an 89% complete response rate with investigational NXC-201 in relapsed/refractory AL amyloidosis...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026 /PRNewswire...

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immix Biopharma, Inc. (Immix or the Company) (NASDAQ: IMMX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026 /PRNewswire...

All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy

Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.read more...

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Bearish Sentiment

<ul class="summary-bullets"><li>BofA raised its price target on Immix to $30 from $27 while maintaining a ‘Buy’ rating, according to The Fly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>NXC-201 delivered an 89% complete response rate, with no relapses.</li><li>&nbsp;Immix announced a $125 million stock offering to provide additional funding for the development of NXC-201.</li></ul>Immix Biopharma (<a class="mention" data-mention="$IMMX" data-symbol-id="IMMX" href="https://stocktwits.com/symbol/IMMX" target="_blank">IMMX</a>) was in focus on Tuesday as BofA grew more confident in the prospects for its lead CAR-T therapy, NXC-201, following encouraging new clinical data in a rare disease characterized by harmful protein buildup in organs.BofA raised its price target on Immix to $30 from $27 while maintaining a ‘Buy’ rating, according to TheFly. This represents a more than 190% upside potential from current levels.Following the results, the brokerage increased its estimate of NXC-201's odds of success in relapsed/refractory AL amyloidosis. BofA also updated its cash and share count estimates to reflect Immix’s latest equity offering.Despite the positive data, <a href="https://stocktwits.com/symbol/IMMX">IMMX shares</a> were down 11% at the time of writing, and on track for their biggest monthly loss in more than two years. The <a href="https://stocktwits.com/symbol/XBI">State Street SPDR S&amp;P Biotech ETF</a> (XBI) was down 0.5%.<h2 class="st-heading-2">NXC-201 Delivers 89% Complete Response Rate</h2>On Tuesday, Immix said its NXC-201 therapy produced an 89% complete response rate, with 40 of 45 patients achieving a complete response in its Phase 2 Nexicart-2 study. All 25 patients either achieved a complete response or were MRD-negative, meaning no disease was detected using a highly sensitive test. Immix said the complete response rate could eventually rise to 98%.So far, none of the patients who achieved a complete response or became MRD-negative has relapsed, the company said. Immix plans a final readout and a Biologics License Application (BLA) submission with the U.S. Food and Drug Administration (FDA) in mid-2027. NXC-201 has already received FDA Breakthrough Therapy and Orphan Drug designations.<h2 class="st-heading-2">Immix Bolsters Cash Position</h2>Immix also priced an offering of about 11.36 million shares at $11 each, a 4% discount to the stock’s closing price on Monday. The company plans to use the gross proceeds of $125 million primarily for NXC-201 development, working capital and general corporate purposes.Immix had about $232.1 million in cash, cash equivalents and short-term investments as of June 30, plus $2.1 million in long-term Treasury investments.Beyond NXC-201, Immix’s pipeline includes IMX-110, an experimental cancer treatment that has been studied in solid tumors. The company is also developing its N-GENIUS cell-therapy platform for potential treatments across autoimmune and other immune-related diseases.<h2 class="st-heading-2">Retail Turns ‘Bullish’ Despite Slump</h2>Retail sentiment surrounding <a class="mention" data-mention="$IMMX" data-symbol-id="IMMX" href="https://stocktwits.com/symbol/IMMX" target="_blank">IMMX</a> on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.One user said the market is reacting to the share sale since the trial data “was good.”<stembedurl>https://stocktwits.com/Fosco_/message/665334948</stembedurl>The stock has gained around 90% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/space-x-could-deliver-a-q3-beat-says-ubs-here-s-what-s-expected-to-drive-growth/cZMZdXfRBgx">SpaceX Could Deliver A Q3 Beat, Says UBS — Here’s What’s Expected To Drive Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.68
Prev Close	$7.98
Open	$7.86
Dividend Yield	0.00%
50-Day Moving Average	$11.02
Beta	1.36
Avg. Volume	1.68M
PE Ratio	-8.73

52-Week High	$15.10
52-Week Low	$2.85
Market Capitalization	$636.69M
EPS (Annual)	-$0.893
Price to Book	2.40
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMMX Fundamentals